News und Analysen
Why Sage Therapeutics Gained 70% Today
Shares of Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biotech, took flight today, after the company announced positive mid-stage trial results for its moderate-to-severe major depressive....
What Happened in the Stock Market Today
Stocks moved higher on Thursday, with the Dow Jones Industrial Average (DJINDICES: ^DJI) and the S&P 500 (SNPINDEX: ^GSPC) both up a little more than a quarter percentage point.Data source:....
Here's Why Marinus Pharmaceuticals Rose as Much as 41.1% Thursday
Shares of clinical-stage biopharma Marinus Pharmaceuticals (NASDAQ: MRNS) rose over 41% today after larger peer Sage Therapeutics (NASDAQ: SAGE) reported positive top-line results for one of its....
It's Business as Usual at Veeva Systems Inc., and That's Good News for Shareholders
Veeva Systems (NYSE: VEEV) has quickly become a standard-bearer in the pharmaceutical industry. The company was born out of co-founder and CEO Peter Gassner's experience while an executive at....
Why Entellus Medical Inc. Skyrocketed Higher Today
Entellus Medical (NASDAQ: ENTL) is up 50% at 12:33 p.m. EST after announcing that it's being acquired by Stryker (NYSE: SYK) for $24 per share.Stryker's investors seem to think the deal is just....
Allergan Stock Downgraded: What You Need to Know
Every day, Wall Street analysts upgrade some stocks, downgrade others, and "initiate coverage" on a few more. But do these analysts even know what they're talking about? Today, we're taking one....
Is Exelixis, Inc. a Buy?
Yes.I know I'm breaking all the rules about building up suspense, etc. But I think Exelixis (NASDAQ: EXEL) is a buy right now. I think the stock will go higher over the next few years. Don't just....
Is Exact Sciences Corporation (EXAS) a Buy?
Some investors look at a stock that has nearly quadrupled in price within less than 12 months and are excited about buying it. Others look at the same stock and are afraid that the momentum could....
Here's What Caused Sarepta Therapeutics to Shoot 13% Higher In November
A month full of news related to the progress it's making toward helping patients with Duchenne muscular dystrophy (DMD) sparked a 12.9% rally in Sarepta Therapeutics (NASDAQ: SRPT) shares last....
Here's What Caused This Marijuana Stock to Skyrocket 15% in November
Medical marijuana has been used to treat epilepsy in patients for years, but so far, it's efficacy and safety hasn't been supported by a regulatory green light from the Food and Drug....
These 3 Healthcare Stock Dividends Could Soar If Trump Signs a Tax Reform Bill
Now that tax reform bills featuring 20% tax rates have passed the House and Senate, it looks like companies across the country will get to distribute a lot more of the profits they generate. Of....
Here's Why bluebird bio's Shares Soared 24% in November
After bluebird bio (NASDAQ: BLUE) updated investors on the presentations it will be making at a key industry conference soon, its shares jumped 24.2% in November, according to S&P Global....
Why 2017 Was a Year to Forget for Merck & Co. Inc.
Better luck next year. That's what Merck & Co. (NYSE: MRK) is hoping for after a disappointing 2017. Merck stock is down year to date by 7%, while the S&P 500 index is up close to 18%.Will....
2 Top Consumer Staples Stocks to Consider Buying Now -- and 1 to Avoid
Recessions are common enough that you can count on several of them impacting your portfolio over the course of even a 10-year time horizon. That's just one reason why consumer staples stocks --....
Why Immunomedics, Inc. Is Soaring Today
After Immunomedics (NASDAQ: IMMU) shared some positive clinical data with investors, shares of the clinical-stage biotech focused on cancer rose 17% as of 3:10 p.m. EST on Wednesday.Immunomedics....
Why Madrigal Pharmaceuticals Stock Is On Fire Today
Shares of Madrigal Pharmaceuticals (NASDAQ: MDGL) are rocketing higher today after the company announced positive mid-stage results for its experimental non-alcoholic steatohepatitis (NASH)....
BASTIDE : Descriptif du programme de rachat d'actions (AG 30.11.2017)
BASTIDE
Société anonyme au capital de 3.303.261 euros
Siège social :
12, avenue de la Dame, Zone euro 2000
30132 Caissargues
305 635 039 RCS NIMES
Descriptif du programme de rachat d'actions....
BASTIDE : Compte rendu de l'assemblée générale du 30 novembre 2017
BASTIDE LE CONFORT MEDICAL
Société Anonyme au capital de 3.303.261 euros
Siège social : 12, avenue de la Dame, Zone Euro 2000
30132 Caissargues
RCS de NIMES N° B 305 635 039
Compte rendu de....
The Motley Fool Interviews Trupanion Founder and CEO Darryl Rawlings
Trupanion (NASDAQ: TRUP) is one of the largest medical insurance providers for cats and dogs with over 400,000 pets enrolled. However, that represents only a small portion of the over 150 million....
This Double Whammy Caused Regeneron Pharmaceuticals Inc. to Fall 10% in November
Shares of Regeneron Pharmaceuticals (NASDAQ: REGN), a large-cap biopharmaceutical company that develops treatments for eye disorders and other serious medical conditions, tumbled 10% during the....
ALPHA MOS : Informations relatives au nombre total de droits de vote
INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS PREVUES PAR L'ARTICLE L. 233-8 II DU CODE DE COMMERCE ET L'ARTICLE 223-16 DU REGLEMENT GENERAL DE L'AUTORITE DES MARCHES....
Why DaVita Inc. Jumped Higher Today
DaVita (NYSE: DVA) is up 12.8% at 12:35 p.m. EST after announcing that it's selling its medical group to UnitedHealth Group's (NYSE: UNH) health services business Optum for $4.9 billion.....
Why Alnylam Pharmaceuticals Rose 12.7% in November
In response to the company sharing a slew of positive developments with investors, shares of Alnylam Pharmaceuticals (NASDAQ: ALNY), a clinical-stage biotech focused on RNAi therapies, jumped 13%....
Depomed Executes an Exit Strategy for Its Opioid Drug
After reporting that Collegium Pharmaceutical (NASDAQ: COLL) will take over commercializing its top-selling drug, Nucynta, Depomed Inc. (NASDAQ: DEPO) shares rallied 10% yesterday. The pact is....
Here's Why Editas Medicine Inc. Stock Is Slipping Today
Shares of Editas Medicine Inc. (NASDAQ: EDIT), a biotech that aims to correct disease‑causing genes with CRISPR technology, are in retreat following the pricing of a secondary share offering this....